The study involves a comprehensive analysis of PLK1 inhibition on our panel of DIPG cultures to identify the most promising combinatorial strategies, and test the most effective combinations in our two robust animal models of DIPG. These experiments can then be rapidly translated to clinical trial through the KCA trials centre. The specific aims of the project are to determine the most potent combination therapies which target PLK1 and other key therapeutic pathways (including the RTK/PI3K signalling pathway) in vitro; and to evaluate the efficacy of PLK1 inhibitors in combination with clinically relevant chemotherapeutic drugs using in vivo models of DIPG.
Started: 1 January 2017
Ending: 30 June 2019
